SEPTERNA INC

SEPNNASDAQ

🏆 #1595 by market capEarnings Nov 9US Equity

$342.63▲ $18.47 (+5.39%)

Simulated price

1h—

24h▲ 5.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.75B

Small Cap

📈Revenue Growth (YoY)

+11790.1%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

24.2x

Expensive

Otter Score

Fair

No chart data available for SEPN.

Trading Snapshot

Day Range: $339.62 – $345.17
52-Week Range: $10.62 – $40.65
Volume: $2.80B
Avg Volume: $2.73B
Shares Outstanding: 45.1M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $72M
Last Q Revenue: $17M
P/E Ratio: —
P/S Ratio: 24.2x
EPS (TTM): $-0.82
Dividend Yield: —

Why Investors Own SEPN

✓High-growth profile — revenue up +42.7% YoY with expanding US Equity exposure.
✓Healthy economics — 37% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$72M▲ +43.9% YoY

Gross Margin (TTM)

37.4%▲ +3.9% YoY

Operating Income (TTM)

$20M▲ +43.9% YoY

Free Cash Flow (TTM)

$11M▲ +43.9% YoY

About SEPTERNA INC

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

🦦